Recruiting

Observational Study

Sponsor:

Advanced Integrative Medical Science Institute

Code:

NCT04495790

Conditions

Neoplasms

Neoplasm Malignant

Advanced Cancer

Advanced Solid Tumor

Oncology

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The overall aim is to describe disease-free survival (DFS) in early stage cancer patients and three-year overall survival (OS) outcomes in advanced stage cancer patients receiving Advanced Integrative Oncology (AIO) treatment in a prospective consecutive case series outcomes study. We will collect data and study outcomes for patients with cancer who receive care at AIMS Institute.

Conditions

Neoplasms

Neoplasm Malignant

Advanced Cancer

Advanced Solid Tumor

Oncology

Study ID

NCT04495790

Start date

May 18, 2020

Status verified date

Jan, 2023

Completion date

Dec 31, 2030

Anticipated

Primary completion date

May 18, 2025

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. A new patient coming in for a first office call (FOC) or first consultation via telemedicine with a diagnosis of cancer, or
2. An established patient with a diagnosis of cancer receiving treatment at the AIMS Institute;
3. If over 18 years of age are able to understand study design adequately and provide signed informed consent (IC) to enrollment;
4. If younger than 18 years of age informed assent from the child and informed consent from a parent or guardian who is able to understand the study design adequately and provide signed informed consent for the pediatric patient;
5. A confirmed diagnosis of cancer based on medical oncology medical records.

Exclusion Criteria:

1. Patients not diagnosed with cancer;
2. Telehealth patients;
3. Cannot read or understand English well enough to read and sign the consent form and complete the questionnaires;
4. Unwilling to participate in the AIMS Institute observational study.

Study Design

Enrollment

500 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • AIM 1 (survival) [ Time Frame: 5 Years ]

Central Contacts and Locations

Locations

AIMS Institute

Recruiting

Seattle, Washington, United States, 98102

Contacts

Sunil K Aggarwal, MD, PhD, FAAPMR

2064201321saggarwal@aimsinstitute.net

Principal Investigator:

Therry Eparwa, DNP, ARNP, FNP-BC

More Information

Sponsor

Advanced Integrative Medical Science Institute

Last update posted

Feb 1, 2023

Last verified

Jan, 2023

Keywords

  • Integrative Oncology
  • Naturopathic Oncology
  • Phytomedicine
  • Metabolic Therapy
  • Immunotherapy

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Advanced Integrative Medical Science Institute on 2023-02-01.